Table 6B.

Comparison in monetary terms of high‐cost therapy with pre‐ and post‐implant 21 day infusions of the CardioMEMS system

Potential avoided costs for levosimendan infusions (€)			Potential avoided costs for hospitalizations due to levosimendan infusions (€)			Potential avoided costs (vials + hospitalizations) (€)
Pre‐implant (A)	Post‐implant (B)	(B)–(A)	Pre‐implant (A)	Post‐implant (B)	(B)–(A)	Pre‐implant (A)	Post‐implant (B)	(B)–(A)
0	17 572	17 572	0	51 000	51 000	0	68 572	68 572
0	21 372	21 372	0	72 000	72 000	0	93 372	93 372
0	3350	3350	0	7500	7500	0	10 850	10 850
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	0	0	0	0	0	0	0	0
0	5364	5364	0	27 000	27 000	0	32 364	32 364
0	47 658	47 658	0	157 500	157 500	0	205 158	205 158

The mean of the LION‐HEART study strategy (infusions every 15 days) and the Ortis et al. (infusions every 28 days).